[Zurück]
 
Bitte auswählen
Jahr
Details
Sprache
Sortierung
Ausgabe
neu: RTF !
 Forschungsbericht für das Jahr 2018

Department für Radiologische Diagnostik und Therapie

Klinik für Strahlenheilkunde

Robert Koch Str. 3
79106 Freiburg
Tel: 0049-761-270-9461 Fax: 0049-761-270-9472
Email anca.grosu@uniklinik-freiburg.de


Wissenschaftliche Mitarbeiterinnen und Mitarbeiter

  • Prof. Dr. med. Anca-Ligia Grosu, Ärztliche Direktorin
  • Nils PD Dr. Dr. med. Nicolay, Leitender Oberarzt
  • PD Dr. Dr. med. Nils Nicolay, Leitender Oberarzt
  • Dr. med. Marianne Schmucker, Geschäftsführende Oberärztin
  • Prof. Dr. Dimos Baltas, Leiter der Abt. Medizinische Physik
  • Dr. med. Karl Henne, OA
  • Dr. medic/IM Temeschburg Carmen Martini, OÄ
  • Prof. Dr. med. Ursula Nestle
  • Dr. med. Henning Schäfer, OA
  • Dr. med. Jutta Scholber, OÄ
  • Dr. med. Sonja Adebahr
  • Dr. med. Angelika Bilger
  • Hatice Bunea
  • Dr. med./Univ. Andrei Bunea
  • Jamina Tara Fennell
  • Dr. med. Eleni Gkika
  • Dr. med. Emily Kim
  • Dr. med. Simon Kirste
  • Dr. med. Nicole Landenberger
  • Moritz Luttke, Assistenzarzt
  • Dr. med. Ilinca Popp
  • PD Dr. med. Hans Christian Rischke
  • Nasr Salman
  • Dr. med. Tanja Schimek-Jasch
  • Daniel Schnell
  • Lina Steffan, Assistenzärztin
  • Dr. med. Andreas Thomsen
  • Dr. /VAK Moskau Natascha Volegova-Neher
  • Dr. med. Nicole Wiedenmann
  • Dr. med. Constantinos Zamboglou
  • Amelia Cascajo Castresana
  • Dr. Mark Gainey
  • Dr. rer. nat. Michael Kollefrath
  • Dr. Kodor Koubar
  • Dipl. Phys. Sophie Küchler
  • Dr. Jördis Lübke
  • Dr. Ing. Thomas Rothe
  • Dr. rer. nat. Rolf Wiehle
  • Dr. med. Felix Heinemann, Leiter Klinische und Administrative Informatik
  • Prof. Dr. med. Gabriele Niedermann, Leiterin Sektion Strahlenbiologie
  • Dr. rer. nat. Elke Firat
Einträge in der Rubrik "Who is Who"

Wissenschaftliche Projekte und Forschungsvorhaben


  • Assoziation zw. dem Schweregrad einer Mukositis, der Verängerung verschiedener Speichelparamteter und der zellulären Wundheilungspotenz währen sowie nach einer Strahlentherapie im Kopf-Hals-Bereich
  • CAO/ARO/AIO-12
  • CONKO-07
  • EMR100036-002 Eine offene Phase Ia / Ib-Studie mit dem DNA-PK-Inhibitor MSC2490484A in Kombination mit Strahlentherapie bei Patienten mit fortgeschrittenen soliden Tumoren
  • ESOPEC
  • F-MISO-PET
  • GLIAA - Aminosäure-PET versus MRT gesteuerte Re-Bestrahlung bei Patienten mit rezidiviertem Glioblastoma multiforme - eine randomisierte Phase II klinische Studie -
  • Hipporad MC-Studie
  • L-AP-IS
  • LARIS
  • LungArt
  • LungTech EORTC 22113-08113
  • PEACE 1
  • PEACE 2
  • PEGASUS
  • PET-Plan-Studie
  • PORTAF
  • Tumorspezifische Immunität und Inflammation beim Malignen Melanom
  • Verbundprojekt ZiSStrans: Zielstrukturen der individuellen Strahlenempfindlichkeit, Teilprojekt F

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Adebahr S, Hechtner M, Schrader N, Schimek-Jasch T, Kaier K, Rohr VD, Gkika E, Momm F, Gartner J, Becker G, Grosu AL, Nestle U: Early impact of pulmonary stereotactic fractionated body radiotherapy (SBRT) on Quality of Life (QoL): Benefit for patients with low initial scores (STRIPE trial). J Thorac Oncol, 2018. : http://dx.doi.org/10.1016/j.jtho.2018.10.170 (in Druck)
  • Akbaba S, Oelmann-Avendano JT, Bostel T, Rief H, Nicolay NH, Debus J, Lindel K, Foerster R: Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life. Radiol Oncol, 2018; 52 (3): 320-328. : http://dx.doi.org/10.2478/raon-2018-0029
  • Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB: Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. Bmc Cancer, 2018; 18 (1) (online): 807-807. : http://dx.doi.org/10.1186/s12885-018-4696-8
  • Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E: Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis Liver Cancer, 2018 (online). : http://DOI: 10.1159/000490260
  • Beyer S, Bell E, McElroy J, Fleming J, Cui T, Becker A, Bassett E, Johnson B, Gulati P, Popp I, Staszewski O, Prinz M, Grosu AL, Haque1 S, Chakravarti A: Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas Oncotarget, 2018; 9: 37097-37111.
  • Bilger A, Bretzinger E, Fennell J, Nieder C, Lorenz H, Oehlke O, Grosu AL, Specht HM, Combs SE: Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Med-us, 2018; 7 (6): 2350-2359. : http://dx.doi.org/10.1002/cam4.1486
  • Boda-Heggemann J, Gkika E, Andratschke N, Blanck O, Guckenberger M, Lohr F, Brunner TB: Correspondence on Rajyaguru et al. J Clin Oncol, 2018; 36 (24): 2561-2562. : http://dx.doi.org/10.1200/JCO.2018.78.1542
  • Carles M, Bach T, Torres-Espallardo I, Baltas D, Nestle U, Marti-Bonmati L: Significance of the impact of motion compensation on the variability of PET image features. Phys Med Biol, 2018; 63 (6): 065013-065013. : http://dx.doi.org/10.1088/1361-6560/aab180
  • Chatzikonstantinou G, Zamboglou N, Archavlis E, Strouthos I, Zoga E, Milickovic N, Hilaris B, Baltas D, Rodel C, Tselis N: CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. Strahlenther Onkol, 2018; 194 (12): 1171-1179. : http://dx.doi.org/10.1007/s00066-018-1358-3
  • Combs SE, Bilger A, Diehl C, Bretzinger E, Lorenz H, Oehlke O, Specht HM, Kirstein A, Grosu AL: Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Med-us, 2018; 7 (6): 2319-2327. : http://dx.doi.org/10.1002/cam4.1477
  • Combs SE, Farzin M, Boehmer J, Oehlke O, Molls M, Debus J, Grosu AL: Clinical outcome after high-precision radiotherapy for skull base meningiomas: Pooled data from three large German centers for radiation oncology. Radiother Oncol, 2018; 127 (2): 274-279. : http://dx.doi.org/10.1016/j.radonc.2018.03.006
  • Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rodel CM, Eckert F, Paulsen F, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA: Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med-us, 2018; 7 (5): 1742-1749. : http://dx.doi.org/10.1002/cam4.1425
  • Csanadi A, Oser A, Aumann K, Gumpp V, Rawluk J, Nestle U, Kayser C, Wiesemann S, Werner M, Kayser G: Overexpression of SLC1a5 in lymph node metastases outperforms assessment in the primary as a negative prognosticator in non-small cell lung cancer. Pathology, 2018; 50 (3): 269-275. : http://dx.doi.org/10.1016/j.pathol.2017.10.016
  • De-Colle C, Menegakis A, Monnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Abu Jawad J, Stuschke M, Balermpas P, Rodel C, Grosu AL, Abdollahi A, Debus J, Belka C, Ganswindt U, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D: SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol, 2018; 126 (1): 125-131. : http://dx.doi.org/10.1016/j.radonc.2017.10.008
  • Eichler M, Hechtner M, Wehler B, Buhl R, Stratmann J, Sebastian M, Schmidberger H, Peuser J, Kortsik C, Nestle U, Wiesemann S, Wirtz H, Wehler T, Blettner M, Singer S: Psychological distress in lung cancer survivors at least 1 year after diagnosis-Results of a German multicenter cross-sectional study. Psycho-oncology, 2018; 27 (8): 2002-2008. : http://dx.doi.org/10.1002/pon.4760
  • El Shafie RA, Bougatf N, Sprave T, Weber D, Oetzel D, Machmer T, Huber PE, Debus J, Nicolay NH: Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial. JMIR Res Protoc, 2018; 7 (3) (online): e70. : http://dx.doi.org/10.2196/resprot.8915
  • El Shafie RA, Weber D, Bougatf N, Sprave T, Oetzel D, Huber PE, Debus J, Nicolay NH: Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey. Jmir Mhealth Uhealth, 2018; 6 (8) (online): e10916-e10916. : http://dx.doi.org/10.2196/10916
  • Gainey M, Carles M, Mix M, Meyer PT, Bock M, Grosu AL, Baltas D: Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. Future Oncol, 2018; 14 (8): 737-749. : http://dx.doi.org/10.2217/fon-2017-0464
  • Giordano FA, Welzel G, Siefert V, Jahnke L, Ganslandt T, Wenz F, Grosu AL, Heinemann F, Nicolay NH: Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: What's the PROblem? Oncol Res, 2018; 1: 1-7. : http://dx.doi.org/10.1159/000495294
  • Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB: The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol, 2018; 194 (5): 403-413. : http://dx.doi.org/10.1007/s00066-017-1256-0
  • Gkika E, Oehlke O, Bunea H, Wiedenmann N, Adebahr S, Nestle U, Zamboglou C, Kirste S, Fennell J, Brunner T, Gainey M, Baltas D, Langer M, Urbach H, Bock M, Meyer PT, Grosu AL: Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncol, 2018; 14 (8): 751-769. : http://dx.doi.org/10.2217/fon-2017-0465
  • Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP, Lang SA, Nestle U, Grosu AL, Brunner TB: Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol, 2018. : http://dx.doi.org/10.1007/s00066-018-1385-0 (in Druck)
  • Grosu AL: Diagnostik und Therapie von Hirngliomen Onkologe, 2018. (in Druck)
  • Grosu AL, Schmidtberger H: Gliome Der Onkologe, 2018. (in Druck)
  • Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neuro-oncol, 2018; 140 (2): 385-391. : http://dx.doi.org/10.1007/s11060-018-2964-8
  • Hess J, Unger K, Maihoefer C, Schuttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rodel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C: A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res, 2018. : http://dx.doi.org/10.1158/1078-0432.CCR-18-0776 (in Druck)
  • Hoefflin, Schafer H, et. al: Personalized Clinical Decision Making Through Implementaion of a Molecular Tumor Board: A German Singe-Center Experience JCO PO, 2018 (online). : http://10.1200/PO.18.00105
  • Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X: Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. Hum Gene Ther, 2018. : http://dx.doi.org/10.1089/hum.2017.234 (in Druck)
  • Karagiannis E, Leczynski A, Tselis N, Psanis E, Steckenreiter O, Milickovic N, Bon D, Strouthos I, Ferentinos K, Hass P, Gademann G, Baltas D, Zamboglou N: Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT). Radiother Oncol, 2018; 128 (3): 421-427. : http://dx.doi.org/10.1016/j.radonc.2018.06.003
  • Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W: Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-oncology, 2018; 20 (3): 367-379. : http://dx.doi.org/10.1093/neuonc/nox160
  • Kirmann S, Fahrner H, Bach T, Hall M, Gläß S, Schmucker M, Gkika E, Gainey M, Baltas D, Heinemann F: Digitale Radioonkologie Onkologe, 2018; 24 (5): 390-399.
  • Kirste S, Kayser G, Zipfel A, Grosu AL, Brunner T: Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. Radiat Oncol, 2018; 13 (1): 28-28. : http://dx.doi.org/10.1186/s13014-018-0974-5
  • Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Eich HC, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl KH, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Guckenberger M: Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol, 2018; 127 (2): 246-252. : http://dx.doi.org/10.1016/j.radonc.2018.02.016
  • Lazzeroni M, Bunea H, Grosu AL, Baltas D, Toma-Dasu I, Dasu A: Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. Adv Exp Med Biol, 2018; 1072: 195-200. : http://dx.doi.org/10.1007/978-3-319-91287-5_31
  • Luo R, Wu VWC, He B, Gao X, Xu Z, Wang D, Yang Z, Li M, Lin Z: Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Bmc Cancer, 2018; 18 (1) (online): 575-575. : http://dx.doi.org/10.1186/s12885-018-4348-z
  • Luttke M, Nicolay NH: [Neoadjuvant chemoradiotherapy does not negatively impact the postoperative quality of life of esophageal cancer patients]. Strahlenther Onkol, 2018; 194 (8): 794-796. : http://dx.doi.org/10.1007/s00066-018-1323-1
  • Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pottgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePechoux C, Van Houtte P: ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol, 2018; 127 (1): 1-5. : http://dx.doi.org/10.1016/j.radonc.2018.02.023
  • Nicolay NH: [A close web-based patient follow-up improves overall survival in lung cancer patients]. Strahlenther Onkol, 2018; 194 (6): 604-606. : http://dx.doi.org/10.1007/s00066-018-1297-z
  • Nieder C, Gaspar LE, Ruysscher D, Guckenberger M, Mehta MP, Rusthoven CG, Sahgal A, Gkika E: Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlenther Onkol, 2018; 194 (5): 365-374. : http://dx.doi.org/10.1007/s00066-018-1266-6
  • Nieder C, Hintz M, Bilger A, Oehlke O, Grosu AL: Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). J Clin Med Res, 2018; 10 (3): 178-181. : http://dx.doi.org/10.14740/jocmr3248w
  • Nieder C, Mehta MP, Geinitz H, Grosu AL: Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Crit Rev Oncol Hemat, 2018; 126: 13-18. : http://dx.doi.org/10.1016/j.critrevonc.2018.03.018
  • Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, Grun A, Kramer A, Rodel C, Eckert F, Paulsen F, Kessel KA, Combs SE, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J: Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiother Oncol, 2018; 127 (1): 121-127. : http://dx.doi.org/10.1016/j.radonc.2018.01.011
  • Oria VO, Bronsert P, Thomsen AR, Foll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O: Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl Oncol, 2018; 11 (6): 1307-1322. : http://dx.doi.org/10.1016/j.tranon.2018.08.001
  • Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu AL: Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiother Oncol, 2018. : http://dx.doi.org/10.1016/j.radonc.2018.08.019 (in Druck)
  • Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholoma M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kroger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R: Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med, 2018; 10 (429) (online). : http://dx.doi.org/10.1126/scitranslmed.aam7729
  • Rocha S, Carvalho J, Oliveira P, Voglstaetter M, Schartz D, Thomsen A, Khanduri R, Sanchez J, Keller A, Oliveira C, Nazarenko I: 3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles Adv Sci, 2018. : https://dx.doi.org/10.1002/advs.201800948 (in Druck)
  • Rossi G, Gainey M, Thomann B, Kollefrath M, Wurfel J, Allgaier B, Baltas D: Monte Carlo and experimental high dose rate (192)Ir brachytherapy dosimetry with microDiamond detectors. Z Med Phys, 2018. : http://dx.doi.org/10.1016/j.zemedi.2018.09.003 (in Druck)
  • Ruhle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH: The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. Int J Cancer, 2018; 143 (11): 2628-2639. : http://dx.doi.org/10.1002/ijc.31619
  • Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C: Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med, 2018. : http://dx.doi.org/10.2967/jnumed.118.212563 (in Druck)
  • Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rodel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Lock S: Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clin Cancer Res, 2018; 24 (6): 1364-1374. : http://dx.doi.org/10.1158/1078-0432.CCR-17-2345
  • Schmucker M, Bach T, Gläss S, FahrnerH, Heinemann F: Im Dienste des Patienten: die Digitale Klinik Pflege Zeitschrift, 2018; 71 (4): 22-26.
  • Sprave T, Verma V, Forster R, Schlampp I, Bruckner T, Bostel T, El Shafie RA, Nicolay NH, Debus J, Rief H: Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial. Anticancer Res, 2018; 38 (8): 4961-4968. : http://dx.doi.org/10.21873/anticanres.12814
  • Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie RA, Welzel T, Nicolay NH, Debus J, Rief H: Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial. Bmc Cancer, 2018; 18 (1): 859-859. : http://dx.doi.org/10.1186/s12885-018-4777-8
  • Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie R, Nicolay NH, Debus J, Rief H: Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial. Anticancer Res, 2018; 38 (8): 4953-4960. : http://dx.doi.org/10.21873/anticanres.12813
  • Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie RA, Welzel T, Nicolay NH, Debus J, Rief H: Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol, 2018; 13 (1) (online): 212-212. : http://dx.doi.org/10.1186/s13014-018-1161-4
  • Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Schmid TE, Pigorsch S, Combs SE, Haller B, Balermpas P, Rodel F, Rodel C, Fokas E, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Maihofer C, Monnich D, Zips D, Multhoff G: Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer, 2018; 142: 1911-1925. : http://dx.doi.org/10.1002/ijc.31213
  • Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rodel C, Baltas D, Tselis N: Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol, 2018; 128 (2): 301-307. : http://dx.doi.org/10.1016/j.radonc.2018.04.031
  • Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, Milickovic N, Zamboglou N: High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol, 2018; 126 (2): 270-277. : http://dx.doi.org/10.1016/j.radonc.2017.09.038
  • Su TS, Luo R, Liang P, Cheng T, Zhou Y, Huang Y: A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. Radiother Oncol, 2018; 129 (1): 136-142. : http://dx.doi.org/10.1016/j.radonc.2018.02.031
  • Thomann B, Sachpazidis I, Koubar K, Zamboglou C, Mavroidis P, Wiehle R, Grosu AL, Baltas D: Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. Radiother Oncol, 2018; 127 (1): 62-67. : http://dx.doi.org/10.1016/j.radonc.2018.02.006
  • Thomsen AR, Aldrian C, Bronsert P, Thomann Y, Nanko N, Melin N, Rucker G, Follo M, Grosu AL, Niedermann G, Layer PG, Heselich A, Lund PG: A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Lab Chip, 2018; 18 (1): 179-189. : http://dx.doi.org/10.1039/c7lc00832e
  • Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Moller P, Hartmann S, Hansmann ML, Mackensen A, Schafer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M: Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood, 2018; 132 (26): 2744-2753. : http://dx.doi.org/10.1182/blood-2018-03-836932
  • Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Buchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiat Oncol, 2018; 13 (1) (online): 159-159. : http://dx.doi.org/10.1186/s13014-018-1103-1
  • Zamboglou C, Eiber M, Fassbender T, Eder M, Kirste S, Bock M, Schilling O, Reichel K, van der Heide U, Grosu AL, , PlumX Metrics: Multimodal imaging for radiation therapy planning in patients with primary prostate cancer Physics and Imaging in Radiation Oncology, 2018; 8: 8-16.
  • Zamboglou C, Grosu AL: [Combination of percutaneous radiotherapy, brachytherapy, and androgen deprivation equivalent alternatives to radical prostatectomy for prostate cancer]. Strahlenther Onkol, 2018; 194 (4): 360-362. : http://dx.doi.org/10.1007/s00066-018-1273-7
  • Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL: The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiat Oncol, 2018; 13 (1) (online): 65-65. : http://dx.doi.org/10.1186/s13014-018-1014-1
  • Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL: Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiat Oncol, 2018; 13 (1) (online): 81-81. : http://dx.doi.org/10.1186/s13014-018-1036-8
  • Zhang X, Niedermann G: Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Int J Radiat Oncol, 2018; 101 (1): 63-73. : http://dx.doi.org/10.1016/j.ijrobp.2018.01.094
  • Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Holscher T, Wust P, Ganswindt U, Baur ADJ, Zophel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C: PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiat Oncol, 2018; 13 (1): 90-90. : http://dx.doi.org/10.1186/s13014-018-1047-5
Reviews/Übersichtsartikel in wissenschaftlichen Fachzeitschriften:
Rezensionen:
  • Grosu AL, Fennell J: Morbidität und Letalität durch Meningeome nach kranialer Strahlentherapie in der Kindheit Strahlenther Onkol, 2018; 194 (1) (online): 67-69.
Sonstige Publikationen:
  • Gkika E, Vach W, Adebahr S, Schimek-Jasch T, Brenner A, Brunner TB, Kaier K, Prasse A, Muller-Quernheim J, Grosu AL, Zissel G, Nestle U: Correction: Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? Plos One, 2018; 13 (1) : e0192058-e0192058. : http://dx.doi.org/10.1371/journal.pone.0192058
  • Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O: Correction to: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neuro-oncol, 2018; 140 (2) : 393-393. : http://dx.doi.org/10.1007/s11060-018-2994-2
  • Krauze AV, Attia A, Braunstein S, Chan M, Combs SE, Fietkau R, Fiveash J, Flickinger J, Grosu A, Howard S, Nieder C, Niyazi M, Rowe L, Smart DD, Tsien C, Camphausen K: Correction to expert consensus on re-irradiation for recurrent glioma. Radiat Oncol, 2018; 13 (1) : 8-8. : http://dx.doi.org/10.1186/s13014-018-0955-8
  • Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Buchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL: Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiat Oncol, 2018; 13 (1) . : http://dx.doi.org/10.1186/s13014-018-1134-7

Besondere wissenschaftliche Aktivitäten
Vorsitze und Sprechertätigkeiten:
  • Prof. Dr. med. Anca-L.Grosu, Heinemann F, Röhner F, Schmucker M: Elektronische Krankenakte in der Strahlenheilkunde, DEGRO Ausschuss, seit 09.07.2009.
  • Prof. Dr. med. Anca-L. Grosu: Vorstandsvorsitzende der Hanns-Langendorf-Stiftung, seit 2010.
  • Prof. Dr. med. Anca-Ligia Grosu: Vorstandsmitglied der Deutschen Neuroonkologischen Arbeitsgruppe (NOA), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des unabhängigen Expertengremiums der Deutschen Gesellschaft für Radioonkologie (DEGRO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Arbeitsgemeinschaft Radiologische Onkologie (ARO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des Geschäftsführenden Vorstands des Comprehensive Cancer Centers, Universitätsklinikum Freiburg (CCCF), seit 2012.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Beirat des Comprehensive Cancer Centers Graz (CCC Graz), Österreich, seit 2014.
  • Prof. Dr. med. Anca-Ligia Grosu: Stellvertretende Vorsitzende des Deutschen Konsortiums für Translationale Krebsmedizin, Universitätsklinikum Freiburg (DKTK Partnerstandort Freiburg) , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Senat der Albert-Ludwigs-Universität Freiburg , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Radiotherapy and Oncology" (The Green Journal), seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktion der Fachzeitschrift "Strahlentherapie und Onkologie", seit 2016.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Physics and Imaging in Radiation Oncology", seit 01.08.2016.
  • Prof. Dr. med. Ursula Nestle: Vorsitzende des Ausschusses "Strahlenschutz in der Medizin" Strahlenschutzkommission , seit 2015.

Abschlussarbeiten